What if I do not want to take medication?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Declining medication is your decision, and for several endocrine conditions there is real non-drug management: 5 to 7 percent weight loss with activity for insulin resistance, resistance training for muscle and bone, cognitive behavioural therapy and clinical hypnosis for hot flashes. For overt hypothyroidism, type 1 diabetes, severe hyperthyroidism and osteoporosis after fracture, declining carries genuine risk.
Get urgent care if: you have declined or stopped treatment and develop any of the following.
- Extreme drowsiness, confusion, very low body temperature or slowed breathing in someone with untreated hypothyroidism
- Nausea, vomiting, deep rapid breathing, abdominal pain or drowsiness in someone with type 1 diabetes, which can indicate diabetic ketoacidosis
- A fast or irregular heartbeat, chest pain, high fever or marked agitation in someone with untreated hyperthyroidism
- Sudden back pain or a loss of height in someone with osteoporosis, which can indicate a vertebral fracture
Declining a medication is a decision you are entitled to make, and for several endocrine conditions there is genuine non-drug management with evidence behind it. The clinician's job is not to overrule you. It is to make sure the decision is informed, which means being specific about what the alternative can achieve, how long it takes, what will be measured, and where declining carries real rather than theoretical risk.
What non-drug management looks like
For insulin resistance and prediabetes the evidence is strong. In the Diabetes Prevention Program, a structured lifestyle program lowered progression to type 2 diabetes by 58 percent over about three years compared with placebo. In participants aged 60 and over the reduction was 71 percent. Metformin in the same trial lowered progression by 31 percent. The NIDDK describes the target as losing 5 to 7 percent of starting weight alongside regular physical activity. That is a real alternative to a drug, and in that trial it outperformed the drug.
Thyroid, PCOS and perimenopause
The picture differs by condition. In Hashimoto's thyroiditis with a TSH still in range, there is no medication to decline yet and monitoring is the management. In PCOS, the 2023 international evidence-based guideline places lifestyle and, where relevant, weight management as the foundation, with medication added for specific goals such as ovulation, cycle regulation or hirsutism. In perimenopause, the 2023 nonhormone therapy position statement of The North American Menopause Society gives its highest evidence rating to cognitive behavioural therapy, clinical hypnosis, SSRIs, SNRIs, gabapentin and fezolinetant for hot flashes. Two of those six recommended options are not drugs at all.
Where declining carries real risk
Four situations are different, and a clinician has to be direct about them. Untreated overt hypothyroidism can progress to myxedema coma, which the NIDDK describes as an extreme form in which the body's functions slow to a life-threatening point. Type 1 diabetes requires insulin; the NIDDK states that people with type 1 need insulin to stay alive. Untreated Graves' disease and other causes of severe hyperthyroidism can cause a rapid irregular heartbeat leading to blood clots, stroke and heart failure, as well as thinning bones. Osteoporosis with a previous fragility fracture carries a high risk of the next fracture, and no diet or exercise program substitutes for treatment there.
| Condition | What non-drug management can do | What declining risks |
|---|---|---|
| Prediabetes and insulin resistance | 5 to 7 percent weight loss with activity; 58 percent lower progression in the DPP | Progression to type 2 diabetes, usually slowly |
| PCOS | Lifestyle and weight management as the foundation of the 2023 guideline | Continued anovulation and rising metabolic risk over years |
| Hot flashes in perimenopause | Cognitive behavioural therapy and clinical hypnosis, both Level I in 2023 | Symptoms persist; no acute danger |
| Overt hypothyroidism | Nothing replaces levothyroxine | Progression, and rarely myxedema coma |
| Type 1 diabetes | Nothing replaces insulin | Diabetic ketoacidosis and death |
| Osteoporosis after a fracture | Exercise, protein and vitamin D support treatment | A further fracture |
Say at the first visit that you would rather not take medication, before a prescription is sent. It changes what gets ordered and how progress is tracked, and a trial of non-drug management with a defined endpoint and a review date is a legitimate plan. Declining to be measured is the part that is not.
The clinical detail
Monitoring intervals matter more when medication is declined. In subclinical hypothyroidism with positive TPO antibodies, TSH and free T4 are usually rechecked every 6 to 12 months, because antibody positive patients progress to overt hypothyroidism more often. In prediabetes, HbA1c is typically repeated annually, and sooner when the value sits close to 6.5 percent. In osteopenia, the interval to the next bone density scan depends on the T-score and risk factors rather than on a fixed schedule.
The Diabetes Prevention Program figures give the size of what structured lifestyle change achieved: a 58 percent reduction in progression to type 2 diabetes overall, 71 percent in participants aged 60 and older, and 31 percent with metformin, over an average of about three years.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Diabetes Prevention Program (DPP), research results. National Institute of Diabetes and Digestive and Kidney Diseases
- Insulin Resistance and Prediabetes. National Institute of Diabetes and Digestive and Kidney Diseases
- The 2023 nonhormone therapy position statement of The North American Menopause Society. The North American Menopause Society, copy hosted by the University of Washington Memory and Brain Wellness Center. PMID 37252752
- Hypothyroidism (Underactive Thyroid). National Institute of Diabetes and Digestive and Kidney Diseases
- Type 1 Diabetes. National Institute of Diabetes and Digestive and Kidney Diseases
- International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, 2023. Monash University, Centre for Research Excellence in Women's Health
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.